Language：English   Publishing type：Research paper (scientific journal)  

No head-to-head postmarket surveillance study has compared the differences in adverse events (AEs) between two combination therapies, axitinib (AXI) + pembrolizumab (PEMBRO) and lenvatinib (LEN) + PEMBRO, against metastatic renal cell carcinoma. This study aims to highlight the comprehensive differences in AEs between these two therapies based on the real-world big data from the Food and Drug Administration Adverse Event Reporting System (FAERS) database. In total, 28 937 records were extracted from the FAERS database, and 139 AEs grouped into the System Organ Class according to the Medical Dictionary for Regulatory Activities were analysed. Logistic regression analyses were performed, and the reporting odds ratio with a 95% confidence interval was determined. We found that the incidences of cardiac and hepatobiliary disorders for AXI + PEMBRO, and blood and lymphatic system, metabolism and nutrition, and vascular disorders for LEN + PEMBRO, all of which were associated with serious AEs, were higher than those for LEN + PEMBRO and AXI + PEMBRO, respectively. The differences in the AEs between AXI + PEMBRO and LEN + PEMBRO were not derived merely from those between AXI and LEN monotherapies. Furthermore, remarkable AE potentiation was observed for AXI + PEMBRO. As FAERS is a spontaneous reporting system comprising partially limited information, analysing more detailed relationships between AEs and patient or treatment characteristics was challenging in this study. The present study is the first to show the overall real-world postmarketing differences in AEs between AXI + PEMBRO and LEN + PEMBRO. Our novel findings will substantially improve clinical practice; we recommend comparing patients' conditions associated with the above AEs when selecting between these two therapies. PATIENT SUMMARY: Herein, we highlight the differences in adverse events (AEs) between axitinib + pembrolizumab and lenvatinib + pembrolizumab therapies using data from the real-world Food and Drug Administration Adverse Event Reporting System database aimed at patients with metastatic renal cell carcinoma. We identified AEs that needed attention in each combination. We recommend the differences in AEs to be considered when selecting these two therapies.

DOI： 10.1016/j.euf.2022.07.003

PubMed

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

AIM: High platelet reactivity (HPR) is associated with increased risks of thrombotic events in patients with coronary artery disease. The recently developed ABCD-GENE score identified five clinical and genetic factors (age, body mass index, chronic kidney disease, diabetes, and the CYP2C19 loss-of-function allele) for HPR, although the significance of various stages of each factor is unclear. METHODS: Four prospective studies were pooled, in which platelet reactivity was measured using the VerifyNow assay with clopidogrel and prasugrel; genotyping of CYP2C19 was also performed. Each component of the ABCD-GENE score was divided into three subcategories. VerifyNow P2Y12 reactivity units ＞208 were defined as HPR. RESULTS: A total of 184 patients were included, of which 111 (60%) and 51 (28%) had HPR with clopidogrel and prasugrel. Chronic kidney disease had an impact on HPR on both clopidogrel and prasugrel, whereas the impact of diabetes was more evident in patients treated with prasugrel. Although the number of CYP2C19 loss-of-function alleles was clearly associated with a likelihood of HPR with clopidogrel, P2Y12 reactivity units with prasugrel treatment were also significantly and progressively higher in patients with more CYP2C19 loss-of-function alleles. CONCLUSIONS: Clinical and genetic factors had a differential effect on a P2Y12 inhibitor reactivity with clopidogrel and prasugrel in patients with coronary artery disease. The severity of the factors also had a different impact on HPR.

DOI： 10.5551/jat.63035

PubMed

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

We evaluated the impact of vonoprazan on blood concentrations of tacrolimus via a retrospective analysis of 52 renal transplant recipients who took tacrolimus and converted from rabeprazole to vonoprazan between August 2018 and September 2019. We compared tacrolimus trough levels upon conversion among groups that were classified based on cytochrome P450 (CYP) gene polymorphisms. CYP3A5 groups were heterozygous or homozygous for CYP3A5∗1 and CYP3A5∗3 alleles. CYP2C19 genotypes were classified as extensive (∗1/∗1), intermediate (∗1/∗2 and ∗1/∗3) or poor metabolizers (∗2/∗2, ∗2/∗3 and ∗3/∗3). Tacrolimus trough levels increased only 0.3 ng/mL upon conversion in the CYP3A5∗3/∗3 group: 5.8 [3.4-7.2] vs 6.1 [3.8-7.9]; p = 0.06. No statistically significance changes in tacrolimus levels also occurred in the CYP3A5∗1/∗1 or CYP3A5∗1/∗3 groups. Subgroup analyses of CYP3A5∗3/∗3 demonstrated low changes for all three CYP2C19 subgroups: 5.2 [4.3-6.5] vs 6.2 [4.3-7.9]; p = 0.07, 6.1 [3.4-7.2] vs 6.7 [4.6-7.9]; p = 0.12 and 5.4 [3.6-6.5] vs 4.7 [3.8-6.3]; p = 1.00, respectively. Conversion to vonoprazan thus resulted in little increase of tacrolimus trough levels, even in the group predicted to be most susceptible (CYP3A5∗3/∗3 and 2C19∗1/∗1), thus supporting the safety of concomitant use of vonoprazan with tacrolimus.

DOI： 10.1016/j.dmpk.2021.100407

PubMed

researchmap

Authorship：Last author   Language：English   Publishing type：Research paper (scientific journal)  

BACKGROUND/AIM: This study aimed to elucidate the detailed characteristics of CYP3A5 expression and the association between CYP3A5 expression and clinical outcomes in patients with renal cell carcinoma (RCC). PATIENTS AND METHODS: This study retrospectively enrolled 124 Japanese patients with RCC treated at the Okayama University Hospital. The commonest CYP3A5 gene polymorphism, CYP3A5*3, and expression levels of CYP3A5 mRNA and protein in each tissue were examined. RESULTS: Expression of CYP3A5 mRNA and protein in RCC tissues was significantly down-regulated compared to that in adjacent normal tissues. High level of CYP3A5 mRNA expression significantly extended cancer-specific survival (p=0.004) and overall survival (p=0.002). The CYP3A5 mRNA expression level was identified as a significant independent prognostic factor for both cancer-specific survival and overall survival. CONCLUSION: CYP3A5 could serve as a potential marker for prognostication and treatment planning for patients with RCC.

DOI： 10.21873/anticanres.15029

PubMed

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

BACKGROUND: High platelet reactivity (HPR) is associated with subsequent thrombotic events in patients undergoing percutaneous coronary intervention (PCI). Recently, the ABCD-GENE score was developed to identify patients at risk for HPR, incorporating both clinical and genetic factors. However, this score was derived and validated in mostly Caucasian subjects and it has not been validated in an East Asian population. METHOD: Individual patient data from 4 prospective studies were pooled, in which platelet reactivity was measured using the VerifyNow assay on clopidogrel and genotyping of CYP2C19 was performed after PCI. Study populations included patients with general stable coronary artery disease, hemodialysis, age ≥75 and/or body weight <50 kg, and acute coronary syndrome. VerifyNow P2Y12 reactivity units >208 was defined as HPR. RESULTS: Of 184 patients, 111 (60%) had HPR on clopidogrel. In the receiver operating characteristics curve analyses, the ABCD-GENE score significantly predicted HPR on clopidogrel (AUC 0.78, best cut-off value 9, p < 0.001). Across the 4 studies and their combinations, the diagnostic ability and cut-off values of ABCD-GENE score for HPR on clopidogrel were consistent. CONCLUSIONS: The ABCD-GENE score had significant and moderate diagnostic ability for HPR on clopidogrel in Japanese patients undergoing PCI. The predictivity was consistent across a broad spectrum of patient populations, suggesting the applicability of this novel scoring system in clinical practice worldwide.

DOI： 10.1016/j.ijcard.2020.11.022

PubMed

researchmap

Language：Japanese   Publisher：(一社)日本医学教育学会  

researchmap

Other Link： https://search.jamas.or.jp/index.php?module=Default&action=Link&pub_year=2020&ichushi_jid=J00050&link_issn=&doc_id=20201106070007&doc_link_id=%2Fed9jmded%2F2020%2F005105%2F008%2F0541-0543%26dl%3D0&url=https%3A%2F%2Fwww.medicalonline.jp%2Fjamas.php%3FGoodsID%3D%2Fed9jmded%2F2020%2F005105%2F008%2F0541-0543%26dl%3D0&type=MedicalOnline&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00004_2.gif

Authorship：Last author   Language：English   Publishing type：Research paper (scientific journal)  

Direct-acting antivirals, asunaprevir (ASV), daclatasvir (DCV), and beclabuvir (BCV) are known to be mainly metabolized by CYP3A enzymes; however, the differences in the detailed metabolic activities of CYP3A4 and CYP3A5 on these drugs are not well clarified. The aim of the present study was to elucidate the relative contributions of CYP3A4 and CYP3A5 to the metabolism of ASV, DCV, and BCV, as well as the effect of CYP3A5*3 genetic variant in vitro. The amount of each drug and their major metabolites were determined using LC-MS/MS. Recombinant CYP3As and CYP3A5*3-genotyped human liver microsomes (CYP3A5 expressers or non-expressers) were used for the determination of their metabolic activities. The contribution of CYP3A5 to ASV metabolism was considerable compared to that of CYP3A4. Consistently, ASV metabolic activity in CYP3A5 expressers was higher than those in CYP3A5 non-expresser. Moreover, CYP3A5 expression level was significantly correlated with ASV metabolism. In contrast, these observations were not found in DCV and BCV metabolism. To our knowledge, this is the first study to directly demonstrate the effect of CYP3A5*3 genetic variants on the metabolism of ASV. The findings of the present study may provide basic information on ASV, DCV, and BCV metabolisms.

DOI： 10.1038/s10038-019-0685-2

PubMed

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

WHAT IS KNOWN AND OBJECTIVE: We conducted a pilot clinical trial to investigate whether Hangeshashinto (TJ-14) could be substituted for oral alkalization in patients scheduled to undergo chemotherapy by FOLFIRI.3 regimen for colorectal cancer (CRC). METHODS: Patients with CRC were randomized 1:1 to a TJ-14 (7.5 g/day) group or an oral alkalization (sodium bicarbonate, 1.8 g/day; ursodeoxycholic acid, 300 mg/day) group. The primary endpoint was incident of late-onset diarrhoea. A total of 30 patients were randomized to either the TJ-14 group or the alkalization group. RESULTS AND DISCUSSION: There was no statistical difference in age, concomitantly used drugs or UGT1A1 genotypes between the groups. In the alkalization group (n = 15), the frequency of grade 0/1/2 and grade 3 diarrhoea was 73% and 27%, respectively. In the TJ-14 group (n = 14), the frequency of grade 0/1/2 and grade 3 diarrhoea was 79% and 21%, respectively. Grade 4 diarrhoea was not observed in either group. There was no statistically significant difference in other adverse events or in response to FOLFIRI.3 between the groups. WHAT IS NEW AND CONCLUSION: This pilot trial suggests that TJ-14 is a promising alternative treatment option to reduce FOLFIRI.3-induced late-onset diarrhoea, although additional clinical study with a larger number of patients is necessary to confirm these results.

DOI： 10.1111/jcpt.13020

PubMed

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

Paritaprevir (PTV) is a non-structural protein 3/4A protease inhibitor developed for the treatment of hepatitis C disease as a fixed dose combination of ombitasvir (OBV) and ritonavir (RTV) with or without dasabuvir. The aim of this study was to evaluate the effects of cytochrome P450 (CYP) 3A5 on in vitro PTV metabolism using human recombinant CYP3A4, CYP3A5 (rCYP3A4, rCYP3A5) and human liver microsomes (HLMs) genotyped as either CYP3A5*1/*1, CYP3A5*1/*3 or CYP3A5*3/*3. The intrinsic clearance (CLint, Vmax/Km) for the production of a metabolite from PTV in rCYP3A4 was 1.5 times higher than that in rCYP3A5. The PTV metabolism in CYP3A5*1/*1 and CYP3A5*1/*3 HLMs expressing CYP3A5 was comparable to that in CYP3A5*3/*3 HLMs, which lack CYP3A5. CYP3A4 expression level was significantly correlated with PTV disappearance rate and metabolite formation. In contrast, there was no such correlation found for CYP3A5 expression level. This study represents that the major CYP isoform involved in PTV metabolism is CYP3A4, with CYP3A5 having a minor role in PTV metabolism. The findings of the present study may provide foundational information on PTV metabolism, and may further support dosing practices in HCV-infected patients prescribed PTV-based therapy.

DOI： 10.1080/00498254.2018.1524947

PubMed

researchmap

Authorship：Last author  

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

BACKGROUND: High on-treatment platelet reactivity (HPR) under clopidogrel treatment is frequently observed in hemodialysis (HD) patients. In such patients, 10mg of prasugrel has reportedly inhibited platelet reactivity more adequately compared with 75mg of clopidogrel. However, the efficacy of 3.75mg prasugrel in Japanese HD patients is largely unknown. METHODS: A total of 41 Japanese coronary artery disease patients under HD who received aspirin and clopidogrel were enrolled. Clopidogrel was switched to 3.75mg prasugrel. At day 14, prasugrel was switched to clopidogrel. Platelet reactivity was measured using VerifyNow assay (Accumetrics, San Diego, CA, USA) at baseline, day 14, and day 28. VerifyNow P2Y12 reaction units (PRU) >208 was defined as HPR. RESULTS: The PRU level on prasugrel therapy was significantly lower than that on clopidogrel therapy before switching (219.1±62.3 PRU vs. 238.2±68.0 PRU, p=0.02). Although the prevalence of HPR was numerically lower on prasugrel therapy compared with clopidogrel therapy before and after switching, the differences did not reach a statistical significance (57.6% vs. 75.7% vs. 74.2%, p=0.13). Even under prasugrel treatment, more than half of patients showed HPR. CONCLUSIONS: Although low-dose prasugrel had somewhat better antiplatelet effect than clopidogrel, it could not significantly improve the prevalence of HPR in Japanese HD patients. Higher doses of prasugrel might be needed to achieve adequate platelet inhibition in this high thrombotic risk population.

DOI： 10.1016/j.jjcc.2018.07.001

PubMed

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

BACKGROUND: Due to concern about bleeding complications, a maintenance dose of prasugrel 2.5 mg may be used in elderly or low-body-weight patients in Japan. There is little information, however, on the efficacy and safety of a 2.5-mg maintenance dose of prasugrel. Methods and Results: In this single-center, prospective, open-label, cross-over study, a total of 44 elderly (≥75 years old) or low body-weight (<50 kg) Japanese patients >1 month after percutaneous coronary intervention who were treated with aspirin 81-100 mg and clopidogrel 75 mg were randomized to either prasugrel 2.5 mg or 3.75 mg instead of clopidogrel for 14 days, with a cross-over directly to the alternate treatment for another 14 days. Platelet inhibition was assessed with the VerifyNow assay (Accumetrics, San Diego, CA, USA) at 3 time points: baseline; day 14; and day 28. P2Y12 reaction units (PRU) ≤95 was defined as low on-treatment platelet reactivity (LPR), and PRU ≥262 as high on-treatment platelet reactivity (HPR). The prevalence of LPR was 2.2% in patients treated with clopidogrel, 2.2% in those with prasugrel 2.5 mg, and 22.7% in those with prasugrel 3.75 mg (P<0.001). Clopidogrel resulted in the higher prevalence of HPR compared with 2.5-mg and 3.75-mg prasugrel (40.9% vs. 18.2% vs. 6.8%, P<0.001). CONCLUSIONS: Prasugrel 2.5 mg may be more appropriate in elderly or lower-body-weight Japanese patients.

DOI： 10.1253/circj.CJ-18-0337

PubMed

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

The PRASFIT-ACS study showed the antiplatelet effect 2-4 h after prasugrel loading. However, there is little information about the antiplatelet effect <2 h after prasugrel loading dose, especially in patients with acute coronary syndrome (ACS). There had not been any comparison between ST-segment elevation myocardial infarction (STEMI) and non-ST-segment elevation ACS (NSTE-ACS). Fifty patients with ACS (15 with STEMI and 35 with NSTE-ACS) were enrolled. They received a 20-mg prasugrel loading dose followed by a maintenance dose of 3.75 mg. Platelet reactivity [P2Y12 reaction units (PRU)] was evaluated by the VerifyNow assay at baseline, 30 min, 1, 2, 4, and 6 h, 1 week under prasugrel, and at 1 month after switching to clopidogrel. The primary end point was the change of PRU compared to the baseline. Furthermore, PRU after prasugrel loading between STEMI and NSTE-ACS was compared. A significant reduction in PRU from baseline was observed at ≥2 h after administration of prasugrel. In STEMI patients, a significant reduction in PRU was observed at 4 h after prasugrel loading. STEMI patients had higher PRU compared to NSTE-ACS patients at 2, 4, and 6 h after prasugrel loading. Utilizing >208 PRU as a cutoff value, STEMI patients had a higher prevalence of high on-treatment platelet reactivity at 2-6 h and 1 week after loading. Rapid antiplatelet effect is not achieved by low-dose prasugrel loading in STEMI patients. Platelet inhibition occurs earlier in NSTE-ACS patients, although it takes ≥2 h after loading in the majority of patients.

DOI： 10.1007/s12928-017-0475-8

PubMed

researchmap

Language：English   Publisher：国際医療福祉大学学会  

researchmap

Other Link： https://search.jamas.or.jp/index.php?module=Default&action=Link&pub_year=2018&ichushi_jid=J05958&link_issn=&doc_id=20180426420014&doc_link_id=http%3A%2F%2Fid.nii.ac.jp%2F1065%2F00000857%2F&url=http%3A%2F%2Fid.nii.ac.jp%2F1065%2F00000857%2F&type=%8D%91%8D%DB%88%E3%97%C3%95%9F%8E%83%91%E5%8Aw%81F%8D%91%8D%DB%88%E3%97%C3%95%9F%8E%83%91%E5%8Aw%83%8A%83%7C%83W%83g%83%8A&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F80077_3.gif

Language：English   Publishing type：Research paper (scientific journal)  

DOI： 10.1016/j.jiac.2017.08.004

Web of Science

PubMed

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

BACKGROUND: The impact of chronic kidney disease (CKD) on the antiplatelet effect of clopidogrel and low-dose (3.75mg) prasugrel in Japanese patients is largely unknown. METHODS: A total of 53 consecutive Japanese patients with stable coronary artery disease who received aspirin and clopidogrel were enrolled, and categorized by estimated glomerular filtration rate (eGFR): CKD group (n=15, eGFR<60ml/min/1.73m2) and non-CKD group (n=38, eGFR≥60ml/min/1.73m2). Clopidogrel was switched to 3.75mg prasugrel. Platelet reactivity measurement using the VerifyNow P2Y12 assay (Accumetrics, San Diego, CA, USA) was performed at baseline (on clopidogrel) and day 14 (on prasugrel). RESULTS: The VerifyNow P2Y12 reaction units (PRU) during clopidogrel therapy was significantly higher in the CKD group than that in the non-CKD group (185.2±51.1 PRU vs. 224.3±57.0 PRU, p=0.02), whereas, the PRU with the prasugrel therapy in the CKD group and non-CKD group were not significantly different (149.9±51.1 PRU vs. 165.3±61.8 PRU, p=0.36). The PRU was significantly lower with the prasugrel therapy compared to that with the clopidogrel therapy both in the CKD group and in the non-CKD group. CONCLUSIONS: Antiplatelet effect of clopidogrel but not prasugrel is attenuated in patients with CKD. Prasugrel achieves a consistently lower platelet reactivity compared with clopidogrel regardless of the presence of mild to moderate CKD.

DOI： 10.1016/j.jjcc.2016.07.017

PubMed

researchmap

Language：Japanese   Publisher：(一社)日本病院薬剤師会  

researchmap

Other Link： https://search.jamas.or.jp/index.php?module=Default&action=Link&pub_year=2017&ichushi_jid=J04451&link_issn=&doc_id=20170414280005&doc_link_id=%2Fdg4hppha%2F2017%2F005304%2F003%2F0417-0422%26dl%3D0&url=https%3A%2F%2Fwww.medicalonline.jp%2Fjamas.php%3FGoodsID%3D%2Fdg4hppha%2F2017%2F005304%2F003%2F0417-0422%26dl%3D0&type=MedicalOnline&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00004_2.gif

Language：Japanese   Publisher：(一社)日本医療薬学会  

researchmap

Other Link： https://search.jamas.or.jp/index.php?module=Default&action=Link&pub_year=2016&ichushi_jid=J03520&link_issn=&doc_id=20161125520003&doc_link_id=%2Fdb5pharm%2F2016%2F004211%2F003%2F0738-0745%26dl%3D0&url=https%3A%2F%2Fwww.medicalonline.jp%2Fjamas.php%3FGoodsID%3D%2Fdb5pharm%2F2016%2F004211%2F003%2F0738-0745%26dl%3D0&type=MedicalOnline&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00004_2.gif

Language：English   Publishing type：Research paper (scientific journal)  

Web of Science

researchmap

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

BACKGROUND: The pharmacodynamic effects of changing from standard-dose clopidogrel to low-dose (3.75 mg) prasugrel in Japanese patients are largely unknown. METHODS AND RESULTS: A total of 53 consecutive Japanese patients with stable coronary artery disease (CAD) who received aspirin and clopidogrel were enrolled. Clopidogrel was switched to 3.75 mg prasugrel. At day 14, prasugrel was switched to 75 mg clopidogrel. Platelet reactivity was measured using the VerifyNow assay at baseline, day 14, and day 28. VerifyNow P2Y12 reaction units (PRU) >208 was defined as high on-treatment platelet reactivity (HPR). The prevalence of HPR (18.9% vs. 41.5% vs. 44.2%, P<0.001) and the PRU level (154.3±54.2 vs. 196.2±55.5 vs. 194.6±55.8, P<0.001) were significantly lower on prasugrel maintenance therapy compared with the clopidogrel therapy before and after switching. The CYP2C19 genotypes that account for the 3 phenotypes (ie, extensive metabolizer, intermediate metabolizer, and poor metabolizer) had a significant impact on platelet reactivity with clopidogrel (174.9±54.0 vs. 193.1±56.5 vs. 240.6±25.4 PRU, P<0.001) but not prasugrel (147.0±51.9 vs. 147.5±58.3 vs. 184.4±38.3 PRU, P=0.15). CONCLUSIONS: Low-dose prasugrel achieves stronger platelet inhibition than clopidogrel in Japanese patients with stable CAD.

DOI： 10.1253/circj.CJ-15-0546

PubMed

researchmap

Authorship：Lead author  

researchmap

Language：Japanese   Publisher：(一社)日本病院薬剤師会  

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

INTRODUCTION: Antiplatelet effects of clopidogrel appear to be affected by various factors including genetic polymorphism. So far, there has been little information about the response of clopidogrel in Asians, whose prevalence of a CYP2C19 loss-of-function (LOF) allele is high. METHODS AND RESULTS: We investigated background and clinical factors affecting on-clopidogrel platelet reactivity in Japanese patients undergoing coronary stent implantation (n=114). In univariate analysis, antiplatelet effects of clopidogrel in a steady state were associated with not only CYP2C19 genotypes but also several factors including dyslipidemia. In addition, we developed an algorithm that can estimate P2Y12 Reaction Units (PRU) in a steady state by multiple regression analysis and evaluated the adequacy of the algorithm by the Akaike Information Criterion. CONCLUSIONS: We revealed several factors influencing on-clopidogrel platelet reactivity in Japanese patients. We also succeeded in developing an algorithm that estimates PRU in a steady state, although it is uncertain whether the algorithm can be applied to other populations.

DOI： 10.1016/j.thromres.2014.07.018

PubMed

researchmap

Language：Japanese   Publisher：(一社)日本TDM学会  

researchmap

Language：Japanese   Publisher：(公社)日本化学療法学会  

researchmap

Language：English  

Web of Science

researchmap

Language：Japanese   Publishing type：Research paper (scientific journal)   Publisher：Chiba Medical Society  

Scopus

researchmap

Language：English   Publisher：Nature Publishing Group  

CiNii Article

CiNii Books

researchmap

Other Link： http://search.jamas.or.jp/link/ui/2014058864

Language：Japanese   Publisher：(一社)日本病院薬剤師会  

researchmap

Language：Japanese   Publisher：(一社)日本医療薬学会  

researchmap

Other Link： https://search.jamas.or.jp/index.php?module=Default&action=Link&pub_year=2013&ichushi_jid=J03520&link_issn=&doc_id=20130213430001&doc_link_id=10.5649%2Fjjphcs.39.61&url=https%3A%2F%2Fdoi.org%2F10.5649%2Fjjphcs.39.61&type=J-STAGE&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00007_3.gif

researchmap

Language：Japanese   Publisher：(一社)日本病院薬剤師会  

researchmap

Language：Japanese   Publisher：(一社)日本TDM学会  

researchmap

Language：Japanese   Publisher：(一社)日本病院薬剤師会  

researchmap

Language：Japanese   Publisher：(一社)日本病院薬剤師会  

researchmap

Language：Japanese   Publisher：(一社)日本医薬品情報学会  

researchmap

Other Link： https://search.jamas.or.jp/index.php?module=Default&action=Link&pub_year=2012&ichushi_jid=J03839&link_issn=&doc_id=20120620310005&doc_link_id=10.11256%2Fjjdi.14.35&url=https%3A%2F%2Fdoi.org%2F10.11256%2Fjjdi.14.35&type=J-STAGE&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00007_3.gif

Language：English   Publishing type：Research paper (scientific journal)  

DOI： 10.1007/s00726-011-1034-8

Scopus

PubMed

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

DOI： 10.1124/dmd.111.039586

Web of Science

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

DOI： 10.1159/000330076

Scopus

PubMed

researchmap

Language：Japanese   Publisher：(一社)日本病院薬剤師会  

researchmap

Language：Japanese   Publisher：(一社)日本医薬品情報学会  

researchmap

Other Link： https://search.jamas.or.jp/index.php?module=Default&action=Link&pub_year=2010&ichushi_jid=J03839&link_issn=&doc_id=20101213330003&doc_link_id=10.11256%2Fjjdi.12.69&url=https%3A%2F%2Fdoi.org%2F10.11256%2Fjjdi.12.69&type=J-STAGE&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00007_3.gif

Language：English   Publishing type：Research paper (scientific journal)  

AIM: Kefiran is an exopolysaccharide produced by Lactobacillus kefiranofaciens, and has been proposed to have many health-promoting properties. We investigated the antiatherogenic effect of kefiran on rabbits fed a high-cholesterol diet. METHODS: Male New Zealand White rabbits were fed a 0.5% cholesterol diet without (control group, n = 7) or with kefiran (kefiran group, n = 8) for eight weeks. The aorta was analyzed by histochemistry and atherosclerotic lesions were quantified. Lipids and sugars in serum were measured. Foam cell formation of RAW264.7 by βVLDL derived from both groups of rabbits was also investigated. RESULTS: Cholesterol, triglyceride and phospholipids levels of serum and lipoprotein fractions were not significantly different between these groups. Atherosclerotic lesions of the aorta in the kefiran group were statistically lower than those of the control group, with marked differences in the abdominal aorta. T-lymphocytes were not detectable in the aorta of the kefiran group. Cholesterol contents in stools were almost identical in both groups. Cholesterol content in the liver of the kefiran group was statistically lower than in the control group. Galactose content of βVLDL derived from the kefiran group was higher, and the lipid peroxidation level was much lower than in the control group. RAW264.7 macrophages treated with βVLDL from the kefiran group showed a more spherical shape and accumulated statistically lower cholesterol than macrophages treated with βVLDL from the control group. CONCLUSION: Orally derived kefiran is absorbed in the blood. Kefiran prevents the onset and development of atherosclerosis in hypercholesterolemic rabbits by anti-inflammatory and anti-oxidant actions.

PubMed

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

INTRODUCTION: Several factors responsible for inter-individual differences in response to warfarin have been confirmed; however, unidentified factors appear to remain. The purpose of this study was to examine a simple method to evaluate whether optional variables are appropriate as factors to improve dosing algorithms. MATERIALS AND METHODS: All patients were Japanese. Genotyping of selected genes was conducted, and other information was obtained from medical record. Dosing algorithms were constructed by multivariate linear regression analyses and were evaluated by the Akaike Information Criterion (AIC). RESULTS AND CONCLUSIONS: Multivariate analysis showed that white blood-cell count (WBC), concomitant use of allopurinol, and CYP4F2 genotype are apparently involved in warfarin dose variation, in addition to well-known factors, such as age and VKORC1 genotype. We evaluated the adequacy of these variables as factors to improve the dosing algorithm using the AIC. Addition of WBC, allopurinol administration and CYP4F2 genotype to the basal algorithm resulted in decreased AIC, suggesting that these factor candidates may contribute to improving the prediction of warfarin maintenance dose. This study is the first to evaluate the warfarin dosing algorithm by AIC. To further improve the dosing algorithm, AIC may be a simple and useful tool to evaluate both the model itself and factors to be incorporated into the algorithm.

DOI： 10.1016/j.thromres.2010.05.016

PubMed

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

BACKGROUND: Tumor lysis syndrome (TLS) is a group of life-threatening metabolic complications that can occur after initiation of cancer chemotherapy. Onset of TLS in the middle of chemotherapy, however, has not been reported previously in patients with hematologic malignancies. OBJECTIVE: We report a case of a patient who experienced TLS of super-acute onset accompanied by hypercytokinemia during chemotherapy treatment with a combination of doxorubicin (Adriamycin), bleomycin, vinblastine, and dacarbazine (ABVD). CASE SUMMARY: A 36-year-old Japanese man (height, 182 cm; weight, 83 kg; body surface area, 2.04 m(2)) was admitted to the hospital for the treatment of malignant lymphoma (clinical stage IVB Hodgkin's lymphoma). Chemotherapy was initiated using the ABVD regimen (doxorubicin [Adriamycin] 25 mg/m(2) by 30-minute infusion, bleomycin 9 mg/m(2) by 30-minute infusion, vinblastine 6 mg/m(2) by bolus injection, and dacarbazine 375 mg/m(2) by 2-hour infusion). During the dacarbazine infusion, the patient's body temperature rose from 36.5 degrees C to 42 degrees C; he experienced a convulsion and then lost consciousness. The convulsion was not suppressed despite the use of diazepam (5 mg IV twice) and phenytoin (500 mg IV). The patient was then transferred to the intensive care unit and sedated using a continuous infusion of midazolam (10 mg/h). Levels of serum lactate dehydrogenase, aspartate aminotransferase, uric acid, blood urea nitrogen, and creatinine evaluated shortly after the ABVD regimen were outside normal limits. In addition, interleukin-6 (IL-6) concentrations were elevated to 54,220 pg/mL. Continuous hemodiafiltration was immediately performed to lower the elevated levels of IL-6. The next day, IL-6 concentrations decreased to 97 pg/mL, and the patient was weaned from ventilator support and sedation. The patient had no adverse effects after the event. According to the results of an assessment using the Naranjo adverse drug reaction probability scale (score = 3), the development of TLS in this patient was possibly related to the chemotherapy regimen. CONCLUSIONS: ABVD chemotherapy was possibly associated with the super-acute onset of TLS in this patient. In addition, hypercytokinemia occurred with TLS, which led to pyrexia, convulsion, and loss of consciousness.

DOI： 10.1016/j.clinthera.2010.03.010

PubMed

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

Steroid sulfatase (STS) is a microsomal enzyme responsible for the formation of 3beta-hydroxysteroid from the corresponding sulfate conjugates. Screening of all exons, exon-intron boundaries and the 5'-flanking region of the STS gene in 93 healthy Japanese individuals was carried out. Among seven single nucleotide polymorphisms (SNPs) identified in this study, six were novel, including one in the untranslated region of exon 1, one in exon 10, and four in the 5'-flanking region. The nonsynonymous SNP (1647G>A) in exon 10 caused amino-acid replacement, Val476Met, with a frequency of 0.014. The allele frequencies of the other SNPs were 0.071 for 155G>A, 0.007 for -21G>A, 0.014 for -1117T>C, 0.106 for -1588G>A, 0.007 for -2427G>A and 0.007 for -2837T>C.

PubMed

researchmap

Authorship：Lead author   Language：English   Publishing type：Research paper (scientific journal)  

Hepatotoxicity is the most frequent adverse drug reaction (ADR) in Japanese treated with ticlopidine (TP). We investigated the relationship between CYP2B6 haplotype and incidence of TP-induced hepatotoxicity in 114 Japanese patients. Although 4 haplotypes (*1A, *1H, *1J and *6B) accounted for more than 80% of the inferred haplotypes in both control (n=81) and case (n=22) subjects, the prevalence was apparently different: control, *1A>*6B>*1H>*1J and case, *1J>*1H>*1A>*6B. The reporter gene assay for the two SNPs, which comprise the *1H or *1J haplotype, suggested that the *1H and *1J haplotypes may be associated with the increased expression of CYP2B6, probably due to g.-2320T>C. Combination analysis of CYP2B6 and human leukocyte antigen (HLA) haplotypes revealed that individuals possessing CYP2B6*1H or *1J with HLA-A*3303 have the highest susceptibility to TP-induced hepatotoxicity (odds ratio, 38.82; 95%CI, 8.08-196.0, P<0.001). Although this is a preliminary case-control study with some limitations, it is the first example that HLA-induced idiosyncratic ADR may be modified by individual variation in CYP activities.

PubMed

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

OBJECTIVE: To report a case in which the serum concentration of vancomycin (VCM) reached the supratherapeutic range following oral administration in a patient with severe pseudomembranous colitis and renal insufficiency. CASE SUMMARY: A 65-year-old, 70 kg weighing man with severe acute pancreatitis and acute renal failure was subjected to continuous hemodiafiltration (CHDF). CHDF could only be performed intermittently because of the unstable circulation dynamic of this patient. After admission, intravenous VCM therapy was initiated. Thereafter, oral VCM administration was begun (0.5 g every 6 h). Despite the discontinuation of intravenous VCM after the first 2 days of oral VCM, the serum VCM concentration increased gradually to 49.8 mg/l over a period of 2 weeks from the initiation of oral administration (34.4 mg/l). Based on pharmacokinetic analysis, the bioavailability of VCM was estimated to over 33%. Autopsy findings indicated broadly distributed necrosis on the lamina propria of the mucosa throughout all parts of the intestine below the duodenum. DISCUSSION: This case indicates necessity of the careful monitoring after oral high-dose VCM administration in a patient with a broadly distributed necrosis and renal insufficiency. CONCLUSIONS: TDM should be considered according to renal function, the severity of enteritis and the total dosage of oral VCM administration.

PubMed

researchmap

Language：Japanese   Publisher：(一社)日本医療薬学会  

researchmap

Other Link： https://search.jamas.or.jp/index.php?module=Default&action=Link&pub_year=2009&ichushi_jid=J03520&link_issn=&doc_id=20090813400004&doc_link_id=10.5649%2Fjjphcs.35.551&url=https%3A%2F%2Fdoi.org%2F10.5649%2Fjjphcs.35.551&type=J-STAGE&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00007_3.gif

Language：Japanese   Publisher：(一社)日本医療薬学会  

researchmap

Other Link： https://search.jamas.or.jp/index.php?module=Default&action=Link&pub_year=2009&ichushi_jid=J03520&link_issn=&doc_id=20090714420004&doc_link_id=%2Fdb5pharm%2F2009%2F003507%2F004%2F0468-0477%26dl%3D0&url=https%3A%2F%2Fwww.medicalonline.jp%2Fjamas.php%3FGoodsID%3D%2Fdb5pharm%2F2009%2F003507%2F004%2F0468-0477%26dl%3D0&type=MedicalOnline&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00004_2.gif

Language：English   Publishing type：Research paper (scientific journal)  

Although rabbit vascular smooth muscle cells (SMCs) showed a differentiated phenotype in three-dimensional type I collagen matrices (honeycombs, diameter of pores=200-500 microm), mouse vascular SMCs proliferated in honeycombs having the same pore size. Here we investigated the relationship between pore sizes of honeycombs and differentiation of SMCs using various pore sizes of honeycombs. Rabbit SMCs (length: 200+/-32 microm) and mouse SMCs (49+/-10 microm) formed crossbridges in honeycombs with 200-300 microm and less than 200 microm of pores, respectively. Both SMCs spread on the inner wall but did not form crossbridges in honeycombs with larger pores. [(3)H]Thymidine incorporation and cell number of both SMCs were decreased when the crossbridges were formed in honeycombs. Because proliferation inhibition and crossbridge formation were observed in the culture of rabbit and mouse SMCs using 200-300 microm and less than 200 microm pore sized honeycombs, respectively, these data suggested that forming crossbridges was important for the inhibition of proliferation of SMCs. Rabbit SMCs differentiation was accompanied by the expression of caldesmon heavy chain when cultured in honeycombs having less than 300 microm pores. Proliferation of mouse SMCs stopped in honeycombs having less than 200 microm pores, but caldesmon heavy chain was not detected despite the expression of its mRNA. Proliferation of SMCs stopped on plates when cells reached confluent state, however, caldesmon heavy chain was not expressed. These data suggested that an appropriate structure and suitable honeycomb pore size are important for the differentiation of SMCs.

DOI： 10.1016/j.mvr.2008.08.006

PubMed

researchmap

Language：Japanese   Publisher：(一社)日本医薬品情報学会  

researchmap

Language：Japanese   Publisher：(一社)日本病院薬剤師会  

researchmap

Language：Japanese   Publisher：(公社)日本薬学会  

researchmap

Other Link： https://search.jamas.or.jp/index.php?module=Default&action=Link&pub_year=2008&ichushi_jid=J01459&link_issn=&doc_id=20080708380011&doc_link_id=110006792638&url=https%3A%2F%2Fci.nii.ac.jp%2Fnaid%2F110006792638&type=CiNii&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00003_3.gif

Language：English   Publishing type：Research paper (scientific journal)  

BACKGROUND: The pharmacologic effects of warfarin might be altered by various factors, including drug-drug interaction. CASE SUMMARY: A 49-year-old Japanese man (height, 174 cm; weight, 68 kg) presented with a 20-month history of malignant lymphoma (diffuse large B cell lymphoma, clinical stage IV). He was treated with a combination of rituximab chemotherapy and etoposide, cisplatin, high-dose cytarabine, and methyl-prednisolone (R-ESHAP). He had been receiving warfarin for the secondary prevention of pulmonary embolism with deep venous thrombosis. When R-ESHAP was started, international normalized ratio (INR) increased from 1 to 5. This phenomenon was observed again in the second R-ESHAP. The INR was increased from 2.44 to 4.71 during chemotherapy but was returned to within the normal range (1.05; normal range: 0.81-1.009) 5 days after chemotherapy was completed. CONCLUSION: In this patient, R-ESHAP chemotherapy might have affected warfarin anticoagulation sensitivity; thus, careful monitoring of INR is essential, particularly in patients receiving warfarin who undergo R-ESHAP chemotherapy.

DOI： 10.1016/j.clinthera.2008.06.008

PubMed

researchmap

Language：Japanese   Publisher：(一社)日本医薬品情報学会  

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

The objectives of this study were to develop a population pharmacokinetic model and to determine the covariates affecting the pharmacokinetics of busulfan in Japanese pediatric patients who received high-dose oral busulfan as a conditioning regimen before hematopoietic stem cell transplantation. Population analysis was performed using retrospective therapeutic drug monitoring data (including test dose data) from 103 children. Their ages ranged from 2 months to 11 years old (mean age, 30 months; median age, 18 months). The plasma concentration of busulfan in all 1028 samples was measured with the same high-performance liquid chromatography method. Maximum likelihood estimates were sought for pharmacokinetic parameters with the NONMEM program. The best structural covariate-free model for busulfan was a one-compartment model with an exponential error model to account for intersubject variability and a proportional error model to account for intrasubject variability. The apparent oral clearance was found to be correlated with age, aspartate transaminase, and type of disease (malignant disease or other). The apparent volume of distribution was related to body weight. The busulfan formulation (1% powder form or crystal form) and dose (milligrams per kilogram) influenced the absorption rate constant. It was estimated that oral clearance expressed per kilogram of body weight is low at early infancy, then increases to a maximum at approximately 2 years of age and, thereafter, decreases. In conclusion, we have developed a population pharmacokinetic model of oral busulfan in children, particularly for those younger than 4 years old, that takes into consideration not only body size, but also several other covariates.

DOI： 10.1097/FTD.0b013e3181621cde

PubMed

researchmap

Language：Japanese   Publisher：(一社)日本病院薬剤師会  

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

Kaposi's varicelliform eruption is the most important problem in treating patients with atopic dermatitis (AD) with tacrolimus ointment. It has been considered that Kaposi's varicelliform eruption occurs due to decreased levels of interleukin (IL)-18. The aim of this study was to examine the relationship between Kaposi's varicelliform eruption and genetic polymorphisms in the IL-18 gene. IL-18 gene promoter polymorphisms were analyzed in 21 AD patients treated with tacrolimus ointment and in 100 healthy volunteers. Six AD patients with Kaposi's varicelliform eruption during the treatment with tacrolimus ointment showed significantly higher frequency in G-to-C mutations at the IL-18 gene promoter region -137 compared with 15 AD patients without Kaposi's varicelliform eruption. The 15 AD patients without Kaposi's varicelliform eruption as well as 100 healthy volunteers did not have mutations of G-to-C at the IL-18 gene promoter region -137. These results suggest that the onset of Kaposi's varicelliform eruption following the treatment with tacrolimus ointment is associated with the mutation of G-to-C in the IL-18 gene promoter region -137, and that caution is required when using tacrolimus ointment for treating AD patients with this mutation.

PubMed

researchmap

Language：Japanese   Publisher：(一社)日本病院薬剤師会  

researchmap

Authorship：Lead author   Language：English   Publishing type：Research paper (scientific journal)  

CYP2C9 is known as an enzyme responsible for the metabolism of various clinically important drugs. Recently, we cloned a cDNA corresponding to a CYP2C9 splicing variant (SV), which seemed to have an open reading frame of a protein with 482 amino acid residues. To investigate whether or not the SV can be translated as a functionally active protein, we expressed the CYP2C9SV in insect cells, and spectrophotometric and enzymatic properties were characterized. The CYP2C9SV protein showed a typical reduced CO-difference spectrum, indicating that the translated protein binds a heme moiety. However, CYP2C9SV did not metabolize tolbutamide or diclofenac at all, suggesting that the SV protein appeared to lack the ability to catalyze reactions mediated by CYP2C9. Although the CYP2C9SV mRNA was detected in all human liver samples examined in this study by real-time PCR, the level was generally low, ranging between 0.7 and 9.6% of the normal CYP2C9 mRNA. These results suggest that the CYP2C9SV protein is unlikely to contribute to CYP2C9 activities, although it appears to be expressed in most individuals.

PubMed

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

DOI： 10.1124/dmd.106.011304

Web of Science

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

CYP3A4 has unusual kinetic characteristics because it has a large active site. CYP3A4 produced more 4-hydroxytriazolam than alpha-hydroxytriazolam at concentrations of more than 60 muM triazolam, and different steroids had different inhibitory effects on the system. To clarify these interesting observations, the interactions between substrate and substrate/steroid were investigated by theoretical calculations. When two triazolam molecules were docked into the active site, the distance between the O-atom and the 4-hydroxylated site was less than the distance to the alpha-hydroxylated site because of interaction between the two triazolam molecules. Estradiol inhibited both alpha- and 4-hydroxytriazolam formation by 50%. Dehydroepiandrosterone (DHEA) inhibited alpha-hydroxylation more than 4-hydroxytriazolam formation, whereas aldosterone had no effect. When one triazolam molecule and one steroid molecule were simultaneously docked, estradiol increased the distance between the O-atom and the two hydroxylated sites, DHEA only increased the distance between the O-atom and alpha-hydroxylated site, and aldosterone did not change the distances. The relevant angles of Fe-O-C in the hydroxylated site of triazolam also widened, together with increased distance. These findings indicate that formation of a substrate and substrate/effector complex in the active site may be a factor for determining the enzyme kinetic parameters of CYP3A4.

PubMed

researchmap

Language：Japanese   Publisher：(一社)日本病院薬剤師会  

researchmap

Language：English  

Web of Science

researchmap

Language：Japanese   Publisher：(一社)日本TDM学会  

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

To anticipate drug-drug interactions by nicardipine in vivo, cytochrome P450 (CYP) forms responsible for the metabolism of nicardipine and inhibition of CYP-dependent drug metabolism by nicardipine were investigated. Microsomes of human B-lymphoblastoid cells expressing each human CYP form were used for the metabolism of nicardipine. Inhibitory effects of nicardipine on drug metabolism were studied using human liver microsomes. CYP2C8, CYP2D6 and CYP3A4 were identified as major CYP forms for the metabolism of nicardipine in human liver microsomes. Nicardipine strongly inhibited two-pathways of triazolam hydroxylation both catalyzed by CYP3A4. Comparison of three Ca(2+) antagonists, nicardipine, nifedipine, and diltiazem revealed that only nicardipine showed such a strong inhibitory potency on the typical CYP2D6-catalyzed drug metabolism. Furthermore, nicardipine inhibited other reactions catalyzed by CYP1A, CYP2A6, CYP2C8, CYP2C9 and CYP2C19 with K(i) values ranging from 1.1 to 29.4 microM. In conclusion, nicardipine was a relatively potent inhibitor of human CYP2D6, CYP3A4 and CYP2C (especially for CYP2C8 and CYP2C19) in vitro, suggesting that drug-drug interactions between nicardipine and other drugs metabolized mainly by these CYP forms appear to occur in vivo.

PubMed

researchmap

Language：Japanese   Publisher：(一社)日本TDM学会  

researchmap

Language：Japanese   Publisher：(一社)日本病院薬剤師会  

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

Web of Science

researchmap

Language：English   Publisher：The Japanese Society for the Study of Xenobiotics  

Limited systematic data on herb-drug interaction are available, despite many opportunities to concomitant use of herb with prescribed drugs. We investigated the effects of 15 herbal extracts in dietary supplements on CYP2C9, CYP2D6 and CYP3A4 activities in human liver microsomes. Strong inhibition of these CYP activities was found by the addition of green tea extracts (GTE) or grape seed extracts (GSE) in vitro. To examine the effects of these extracts on CYP3A activities in vivo, the pharmacokinetics of midazolam (MDZ) was analyzed in rats. Although single treatments with these extracts had negligible effects, 1 week of treatment with them resulted in a significant increase in the ke of intravenously administered MDZ, indicating the induction of CYP3A in the liver. In contrast, 1 week of treatment with GTE, but not GSE, caused a significant increase in the C_max and AUC_0-∞ of orally administered MDZ without change in the t_1/2, suggesting a reduction in CYP3A activity in the small intestines. These studies indicate that subchronic ingestion of GTE or GSE may alter the pharmacokinetics of MDZ, and the effects of GTE on CYP3A activity appear opposite between liver and small intestine, which could not be predicted from in vitro experiments.<br>

DOI： 10.2133/dmpk.19.280

CiNii Article

CiNii Books

researchmap

Other Link： http://search.jamas.or.jp/link/ui/2006149345

Authorship：Lead author   Language：English  

PubMed

researchmap

Language：Japanese   Publisher：(一社)日本病院薬剤師会  

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

DOI： 10.1021/bi034409n

Web of Science

researchmap

Language：Japanese   Publisher：(公社)日本薬学会  

researchmap

Other Link： https://search.jamas.or.jp/index.php?module=Default&action=Link&pub_year=2003&ichushi_jid=J01459&link_issn=&doc_id=20030530520007&doc_link_id=110003614896&url=https%3A%2F%2Fci.nii.ac.jp%2Fnaid%2F110003614896&type=CiNii&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00003_3.gif

Language：English   Publishing type：Research paper (scientific journal)  

DOI： 10.1124/dmd.31.4.432

Web of Science

researchmap

Language：English   Publishing type：Research paper (scientific journal)   Publisher：Japan Epidemiology Association  

DOI： 10.2188/jea.13.176

Scopus

PubMed

CiNii Article

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

DOI： 10.1097/00008571-200211000-00011

Web of Science

researchmap

Authorship：Lead author   Language：English   Publishing type：Research paper (scientific journal)  

Web of Science

researchmap

Authorship：Lead author   Language：English   Publishing type：Research paper (scientific journal)  

DOI： 10.1097/00008571-200208000-00012

Web of Science

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

DOI： 10.1097/00008571-200206000-00005

Web of Science

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

DOI： 10.1016/S0003-9861(02)00079-6

Web of Science

PubMed

CiNii Article

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

DOI： 10.1124/dmd.30.5.534

Web of Science

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

DOI： 10.1016/S0006-291X(02)00328-5

Web of Science

PubMed

CiNii Article

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

The relationships between catalytic activity of cytochrome P450 2A6 (CYP2A6), polymorphism of CYP2A6 gene, gender and levels of body iron stores were analysed in a sample group of 202 apparently healthy Thais, aged 19-47 years. Eleven individuals were found to have high activity of CYP2A6, judged by the relatively large amounts (11.2-14.6 mg) of 7-hydroyxcoumarin (7-OHC) excreted 3 h following administration of 15 mg of coumarin. Ten individuals, however, did not excrete any 7-OHC. Of these 10, four were found to have no CYP2A6 gene (whole gene deletion; CYP2A6*4 allele). The frequency of the CYP2A6 alleles; *1A, *1B and *4 in the whole sample group was 52, 40 and 8% while the frequency of the CYP2A6 gene types; *1A/*1A, *1A/*1B, *1B/*1B, *1A/*4, *1B/*4, *4/*4 was 29, 41, 16, 7, 5 and 2%. Subjects having CYP2A6*1A/*1B gene-type group were found to have higher rates of coumarin 7-hydroxylation compared with those of the CYP2A6*1B/*1B and CYP2A6*1A/*4 gene types. The inter-individual variability in CYP2A6 catalytic activity was therefore attributed in part to the CYP2A6 genetic polymorphism. Variation in CYP2A6 activity in this sample group was not associated with gender but, interestingly, it did show an inverse association with plasma ferritin; an indicator of body iron stores. Higher rates of coumarin 7-hydroxylation were found in individuals with low body iron stores (plasma ferritin < 20 microg/l) compared with subjects having normal body iron store status. Subjects (n = 16) with iron overload (plasma ferritin > 300 microg/l) also tended to have elevated rates of coumarin 7-hydroxylation. These results suggest an increased CYP2A6 expression in subjects who have excessive body iron stores. Further investigations into the underlying factors that may lead to increased expression of CYP2A6 in association with abnormal body iron stores are currently in progress in our laboratory.

PubMed

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

Web of Science

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

DOI： 10.1081/DMR-120005668

Web of Science

researchmap

Language：English  

Web of Science

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

DOI： 10.1248/jhs.47.575

Web of Science

CiNii Article

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

Web of Science

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

Web of Science

researchmap

Language：Japanese   Publisher：(一社)日本薬物動態学会  

researchmap

Other Link： https://search.jamas.or.jp/index.php?module=Default&action=Link&pub_year=2001&ichushi_jid=J02023&link_issn=&doc_id=20010925240012&doc_link_id=%2Fco1yakub%2F2001%2F0016s1%2F012%2F5094-5095%26dl%3D0&url=http%3A%2F%2Fwww.medicalonline.jp%2Fjamas.php%3FGoodsID%3D%2Fco1yakub%2F2001%2F0016s1%2F012%2F5094-5095%26dl%3D0&type=MedicalOnline&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00004_2.gif

Language：English  

Web of Science

researchmap

Language：Japanese   Publisher：(一社)日本医療薬学会  

researchmap

Other Link： https://search.jamas.or.jp/index.php?module=Default&action=Link&pub_year=2001&ichushi_jid=J03520&link_issn=&doc_id=20010625030005&doc_link_id=%2Fdb5pharm%2F2001%2F002703%2F005%2F0228-0234%26dl%3D0&url=https%3A%2F%2Fwww.medicalonline.jp%2Fjamas.php%3FGoodsID%3D%2Fdb5pharm%2F2001%2F002703%2F005%2F0228-0234%26dl%3D0&type=MedicalOnline&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00004_2.gif

Language：English   Publisher：福岡医学会  

researchmap

Other Link： https://search.jamas.or.jp/index.php?module=Default&action=Link&pub_year=2001&ichushi_jid=J01325&link_issn=&doc_id=20010910240013&doc_link_id=%2Fdk5fukuo%2F2001%2F009205%2F014%2F0190-0200%26dl%3D0&url=https%3A%2F%2Fwww.medicalonline.jp%2Fjamas.php%3FGoodsID%3D%2Fdk5fukuo%2F2001%2F009205%2F014%2F0190-0200%26dl%3D0&type=MedicalOnline&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00004_2.gif

Language：English   Publishing type：Research paper (scientific journal)  

DOI： 10.1006/bbrc.2001.4422

Web of Science

PubMed

CiNii Article

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

DOI： 10.1006/bbrc.2001.4524

Web of Science

PubMed

CiNii Article

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

DOI： 10.1097/00008571-200102000-00005

Web of Science

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

DOI： 10.1021/tx0001225

Web of Science

PubMed

CiNii Article

researchmap

Language：English   Publisher：The Japanese Society for the Study of Xenobiotics  

Interaction between cytochrome P450 (P450) and other sorts of drug metabolizing enzymes was studied by affinity chromatography with CYP1A1-conjugated column. Solubilized rat liver microsomes were charged onto the column and the eluate was analyzed by immunoblotting. The result showed that the CYP1A1 column effectively trapped microsomal epoxide hydrolase (mEH) and UDP-glucuronosyltransferase (UGT) as well as NADPH-P450 reductase. Non-drug metabolizing enzymes such as calnexin and protein disulfide isomerase did not show any affinity to the column. Neither BSA- nor glycine-conjugated column could trap microsomal protein. These results strongly suggest the specific interaction between P450 and mEH/UGT. When estimated using stereo-selective hydrolysis for styrene oxide as the index, the function of rat mEH was enhanced by co-incubation with CYP1A1, 2B1 and 2C11. The same picture was also seen for the interaction between dog mEH and CYP2B11/3A12. These results suggest that P450 interacts with mEH and UGT to facilitate a series of multistep metabolic conversion.

DOI： 10.2133/dmpk.16.supplement_94

CiNii Article

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

DOI： 10.1097/00008571-200011000-00003

Web of Science

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

DOI： 10.1006/bbrc.2000.2312

Web of Science

PubMed

CiNii Article

researchmap

Language：Japanese   Publisher：The Japanese Society of Clinical Pharmacology and Therapeutics  

DOI： 10.3999/jscpt.31.301

CiNii Article

CiNii Books

researchmap

Other Link： http://search.jamas.or.jp/link/ui/2000210624

Language：English   Publishing type：Research paper (scientific journal)  

Web of Science

researchmap

Language：English  

Web of Science

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

DOI： 10.1006/bbrc.1999.1089

Web of Science

PubMed

CiNii Article

researchmap

Language：English   Publisher：The Japanese Society for the Study of Xenobiotics  

CYP2A6 is known as an enzyme responsible for the metabolism of coumarin. As its toxicological significance, aflatoxin B₁ and NNK are metabolically activated by this CYP to mutagens. In our recent studies, we found that a newly developed drug, SM-12502, was a specific substrate of CYP2A6, and 3 out of 28 Japanese were poor metabolizers (PM) of this drug. Genomic analysis of CYP2A6 gene in the PM indicated that an existence of a new CYP2A6 gene variant which lacks the entire region of open reading frame for the enzyme. The frequency of the individual who possess the mutation homozygously was estimated as 3-4% in Japanese. During the course of investigation of the frequency, we found an another CYP2A6 variant whose 60 by region in the 3'-untranslated region was substituted by the corresponding sequences of CYP2A7 gene. In this study, we investigated the frequency of these polymorphic alleles as well as reported v1 (CYP2A6*2) variant among different race.

DOI： 10.2133/dmpk.14.supplement_100

CiNii Article

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

Web of Science

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

DOI： 10.1016/S1382-6689(98)00007-6

Web of Science

CiNii Article

researchmap

Language：Japanese   Publisher：The Japanese Society of Clinical Pharmacology and Therapeutics  

DOI： 10.3999/jscpt.29.237

CiNii Article

CiNii Books

researchmap

Other Link： http://search.jamas.or.jp/link/ui/1998153014

Authorship：Lead author   Language：English   Publishing type：Research paper (scientific journal)  

DOI： 10.1074/jbc.273.13.7610

Web of Science

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

DOI： 10.1016/S0045-6535(97)00181-1

Web of Science

PubMed

CiNii Article

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

DOI： 10.1016/S1382-6689(97)00025-2

Web of Science

CiNii Article

researchmap

Language：Japanese   Publisher：福岡医学会  

researchmap

Other Link： https://search.jamas.or.jp/index.php?module=Default&action=Link&pub_year=1997&ichushi_jid=J01325&link_issn=&doc_id=19970730500002&doc_link_id=%2Fdk5fukuo%2F1997%2F008805%2F003%2F0144-0148%26dl%3D0&url=https%3A%2F%2Fwww.medicalonline.jp%2Fjamas.php%3FGoodsID%3D%2Fdk5fukuo%2F1997%2F008805%2F003%2F0144-0148%26dl%3D0&type=MedicalOnline&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00004_2.gif

Language：English   Publishing type：Research paper (scientific journal)  

DOI： 10.1016/S0378-4274(97)03881-2

Web of Science

CiNii Article

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

Web of Science

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

Web of Science

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

DOI： 10.1016/S0300-483X(96)03543-3

Web of Science

PubMed

CiNii Article

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

DOI： 10.1016/S0039-128X(96)00153-5

Web of Science

PubMed

CiNii Article

researchmap

Language：Japanese   Publishing type：Research paper (scientific journal)   Publisher：Kyushu University School of Medicine  

Scopus

PubMed

researchmap

Authorship：Lead author   Language：English   Publishing type：Research paper (scientific journal)  

DOI： 10.1080/004982597240136

Scopus

PubMed

researchmap

Language：Japanese   Publishing type：Research paper (scientific journal)   Publisher：Kyushu University School of Medicine  

Scopus

PubMed

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

DOI： 10.1016/0378-4274(96)03668-5

Web of Science

PubMed

CiNii Article

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

Web of Science

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

DOI： 10.1016/0045-6535(95)00316-9

Web of Science

PubMed

CiNii Article

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

DOI： 10.1016/0045-6535(95)00318-5

Web of Science

PubMed

CiNii Article

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

DOI： 10.1006/bbrc.1995.1991

Web of Science

PubMed

CiNii Article

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

Web of Science

researchmap

researchmap

Language：Japanese   Publishing type：Research paper (scientific journal)   Publisher：Kyushu University School of Medicine  

Scopus

PubMed

researchmap

Language：Japanese   Publishing type：Research paper (scientific journal)   Publisher：Kyushu University School of Medicine  

Scopus

PubMed

researchmap

Authorship：Lead author   Language：English   Publishing type：Research paper (scientific journal)  

Web of Science

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

Web of Science

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

DOI： 10.1016/0045-6535(94)90305-0

Web of Science

CiNii Article

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

DOI： 10.1016/0045-6535(93)90140-Z

Web of Science

CiNii Article

researchmap

Authorship：Lead author   Language：English   Publishing type：Research paper (scientific journal)  

DOI： 10.1248/bpb.16.852

Web of Science

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

Web of Science

researchmap

Language：English   Publishing type：Research paper (scientific journal)  

DOI： 10.1248/jhs1956.39.P23

Scopus

researchmap

researchmap

Authorship：Lead author   Language：English   Publishing type：Research paper (scientific journal)  

DOI： 10.3109/00498259209053156

Web of Science

researchmap

Language：English  

Web of Science

researchmap

researchmap

researchmap

researchmap

researchmap

researchmap

researchmap

researchmap

researchmap

researchmap

researchmap

researchmap

researchmap

researchmap

researchmap

researchmap

researchmap

researchmap

Authorship：Last author  

researchmap

Authorship：Last author  

researchmap

Authorship：Corresponding author  

researchmap

researchmap

Authorship：Last author  

researchmap

Authorship：Corresponding author  

researchmap

Authorship：Last author  

researchmap

researchmap

Authorship：Lead author  

researchmap

Authorship：Last author  

researchmap

Authorship：Last author  

researchmap

Authorship：Last author  

researchmap

Authorship：Corresponding author  

researchmap

Authorship：Lead author  

researchmap

Authorship：Corresponding author  

researchmap

Authorship：Last author  

researchmap

Language：Japanese   Publisher：(公社)日本薬学会  

researchmap

Authorship：Corresponding author  

researchmap

Authorship：Corresponding author  

researchmap

Authorship：Corresponding author  

researchmap

Authorship：Corresponding author  

researchmap

Authorship：Lead author  

researchmap

Language：Japanese   Publisher：(株)南山堂  

researchmap

Language：Japanese   Publisher：(公社)日本薬学会  

researchmap

Language：Japanese   Publisher：(株)南山堂  

researchmap

Language：Japanese   Publisher：(公財)薬学研究奨励財団  

researchmap

Language：Japanese   Publisher：日本腎臓病薬物療法学会  

researchmap

Language：Japanese   Publisher：(一社)日本TDM学会  

researchmap

Language：Japanese   Publisher：じほう  

CiNii Article

CiNii Books

researchmap

Other Link： http://search.jamas.or.jp/link/ui/2016170175

Language：Japanese   Publisher：じほう  

CiNii Article

CiNii Books

researchmap

Other Link： http://search.jamas.or.jp/link/ui/2016170176

Language：Japanese   Publisher：(株)南山堂  

researchmap

Language：Japanese   Publisher：(公社)日本薬学会  

researchmap

Language：Japanese   Publisher：(公社)日本薬学会  

researchmap

Language：Japanese   Publisher：(公社)日本薬学会  

researchmap

Language：Japanese   Publisher：(公社)日本薬学会  

researchmap

Language：Japanese   Publisher：(公社)日本薬学会  

researchmap

Language：Japanese   Publisher：(公社)日本薬学会  

researchmap

Language：Japanese   Publisher：(一社)日本エイズ学会  

researchmap

Language：Japanese   Publisher：日本医療薬学会  

CiNii Article

CiNii Books

researchmap

Language：Japanese   Publisher：日本医療薬学会  

CiNii Article

CiNii Books

researchmap

Language：Japanese   Publisher：日本医療薬学会  

CiNii Article

CiNii Books

researchmap

Language：Japanese   Publisher：日本医療薬学会  

CiNii Article

CiNii Books

researchmap

Language：Japanese   Publisher：日本医療薬学会  

CiNii Article

CiNii Books

researchmap

Language：Japanese   Publisher：(一社)国際個別化医療学会  

researchmap

Language：Japanese   Publisher：(NPO)日本急性血液浄化学会  

researchmap

Language：Japanese   Publisher：(一社)日本TDM学会  

researchmap

Language：Japanese   Publisher：(一社)日本TDM学会  

researchmap

Language：Japanese   Publisher：(公社)日本薬学会  

researchmap

Language：Japanese   Publisher：(公社)日本薬学会  

researchmap

Language：Japanese   Publisher：(公社)日本薬学会  

researchmap

Language：Japanese   Publisher：(公社)日本薬学会  

researchmap

Language：Japanese   Publisher：(公社)日本薬学会  

researchmap

Language：Japanese   Publisher：(公社)日本化学療法学会  

researchmap

Language：Japanese   Publisher：(株)ジェフコーポレーション  

researchmap

Language：Japanese   Publisher：千葉医学会  

researchmap

Other Link： https://search.jamas.or.jp/index.php?module=Default&action=Link&pub_year=2014&ichushi_jid=J00810&link_issn=&doc_id=20141229350001&doc_link_id=https%3A%2F%2Fopac.ll.chiba-u.jp%2Fda%2Fcurator%2F900118206%2F&url=https%3A%2F%2Fopac.ll.chiba-u.jp%2Fda%2Fcurator%2F900118206%2F&type=%90%E7%97t%91%E5%8Aw%81F%90%E7%97t%91%E5%8Aw%8Aw%8Fp%90%AC%89%CA%83%8A%83%7C%83W%83g%83%8A_CURATOR&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F80160_3.gif

Language：Japanese   Publisher：(公財)上原記念生命科学財団  

researchmap

Language：Japanese   Publisher：(一社)日本医用マススペクトル学会  

researchmap

Language：Japanese   Publisher：(NPO)日本急性血液浄化学会  

researchmap

Language：Japanese   Publisher：(NPO)日本急性血液浄化学会  

researchmap

Language：Japanese   Publisher：日本医療薬学会  

CiNii Article

CiNii Books

researchmap

Language：Japanese   Publisher：日本医療薬学会  

CiNii Article

CiNii Books

researchmap

Language：Japanese   Publisher：日本医療薬学会  

CiNii Article

CiNii Books

researchmap

Language：Japanese   Publisher：日本医療薬学会  

CiNii Article

CiNii Books

researchmap

Language：Japanese   Publisher：日本医療薬学会  

CiNii Article

CiNii Books

researchmap

Language：Japanese   Publisher：国際医療福祉大学学会  

researchmap

Language：Japanese   Publisher：(一社)日本医薬品情報学会  

researchmap

Language：Japanese   Publisher：(一社)国際個別化医療学会  

researchmap

Language：Japanese   Publisher：(一社)日本TDM学会  

researchmap

Language：Japanese   Publisher：(一社)日本TDM学会  

researchmap

Language：Japanese   Publisher：(株)南山堂  

researchmap

Language：Japanese   Publisher：(一社)日本病院薬剤師会  

researchmap

Language：Japanese   Publisher：(公社)日本薬学会  

researchmap

Language：Japanese   Publisher：(公社)日本薬学会  

researchmap

Language：Japanese   Publisher：(公社)日本薬学会  

researchmap

Language：Japanese   Publisher：(株)医薬ジャーナル社  

researchmap

Other Link： https://search.jamas.or.jp/index.php?module=Default&action=Link&pub_year=2014&ichushi_jid=J00065&link_issn=&doc_id=20140117160020&doc_link_id=10.20837%2F1201401164&url=https%3A%2F%2Fdoi.org%2F10.20837%2F1201401164&type=%88%E3%8F%91.jp_%83I%81%5B%83%8B%83A%83N%83Z%83X&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00024_2.gif

Language：Japanese   Publisher：(一社)日本臨床薬理学会  

researchmap

Language：Japanese   Publisher：日本外科代謝栄養学会  

researchmap

Language：Japanese   Publisher：日本外科代謝栄養学会  

researchmap

Language：Japanese   Publisher：(一社)日本TDM学会  

researchmap

Language：Japanese   Publisher：(公社)日本薬学会  

researchmap

Language：Japanese   Publisher：(一社)日本医療薬学会  

DOI： 10.5649/jjphcs.39.45

CiNii Article

researchmap

Language：Japanese   Publisher：(株)ジェフコーポレーション  

researchmap

Language：Japanese   Publisher：(株)ジェフコーポレーション  

researchmap

Language：Japanese   Publisher：日本医療薬学会  

CiNii Article

CiNii Books

researchmap

Language：Japanese   Publisher：(一社)日本アレルギー学会  

researchmap

Other Link： https://search.jamas.or.jp/index.php?module=Default&action=Link&pub_year=2012&ichushi_jid=J00009&link_issn=&doc_id=20120813110005&doc_link_id=110009489267&url=https%3A%2F%2Fci.nii.ac.jp%2Fnaid%2F110009489267&type=CiNii&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00003_1.gif

Language：Japanese   Publisher：(一社)日本医薬品情報学会  

researchmap

Language：Japanese   Publisher：(株)じほう  

researchmap

Other Link： https://search.jamas.or.jp/index.php?module=Default&action=Link&pub_year=2012&ichushi_jid=J01465&link_issn=&doc_id=20120608340015&doc_link_id=%2Fan1yakgl%2F2012%2F005406%2F019%2F0975-0978%26dl%3D0&url=https%3A%2F%2Fwww.medicalonline.jp%2Fjamas.php%3FGoodsID%3D%2Fan1yakgl%2F2012%2F005406%2F019%2F0975-0978%26dl%3D0&type=MedicalOnline&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00004_2.gif

Language：Japanese   Publisher：(公社)日本薬学会  

researchmap

Language：Japanese   Publisher：(公社)日本薬学会  

researchmap

Language：Japanese   Publisher：(公社)日本薬学会  

researchmap

Language：Japanese   Publisher：(公社)日本薬学会  

researchmap

Language：Japanese   Publisher：(公社)日本薬学会  

researchmap

Language：Japanese   Publisher：(公社)日本薬学会  

researchmap

Language：Japanese   Publisher：(公社)日本薬学会  

researchmap

Language：Japanese   Publisher：(株)ジェフコーポレーション  

researchmap

Language：Japanese  

Scopus

PubMed

researchmap

Language：Japanese   Publisher：日本医療薬学会  

CiNii Article

CiNii Books

researchmap

Language：Japanese   Publisher：日本医療薬学会  

CiNii Article

CiNii Books

researchmap

Language：Japanese   Publisher：日本医療薬学会  

CiNii Article

CiNii Books

researchmap

Language：Japanese   Publisher：日本医療薬学会  

CiNii Article

CiNii Books

researchmap

Language：Japanese   Publisher：日本医療薬学会  

CiNii Article

CiNii Books

researchmap

Language：Japanese   Publisher：(公社)日本生化学会  

researchmap

Language：Japanese   Publisher：(一社)日本TDM学会  

researchmap

Language：Japanese   Publisher：(公社)日本化学療法学会  

researchmap

Language：Japanese   Publisher：(一社)日本アレルギー学会  

researchmap

Other Link： https://search.jamas.or.jp/index.php?module=Default&action=Link&pub_year=2011&ichushi_jid=J00009&link_issn=&doc_id=20110413200015&doc_link_id=%2Fcw4aller%2F2011%2F006003%2F015%2F0329-0329%26dl%3D0&url=https%3A%2F%2Fwww.medicalonline.jp%2Fjamas.php%3FGoodsID%3D%2Fcw4aller%2F2011%2F006003%2F015%2F0329-0329%26dl%3D0&type=MedicalOnline&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00004_2.gif

Language：Japanese   Publisher：(公社)日本薬学会  

researchmap

Language：Japanese   Publisher：(公社)日本薬学会  

researchmap

Language：Japanese   Publisher：(公社)日本薬学会  

researchmap

Language：Japanese   Publisher：(公社)日本薬学会  

researchmap

Language：Japanese   Publisher：(公社)日本薬学会  

researchmap

Language：Japanese   Publisher：(公社)日本薬学会  

researchmap

Language：Japanese   Publisher：(公社)日本薬学会  

researchmap

Language：Japanese   Publisher：(公社)日本薬学会  

researchmap

Language：Japanese   Publisher：(株)ジェフコーポレーション  

researchmap

J-GLOBAL

researchmap

Language：Japanese   Publisher：(公社)日本生化学会  

researchmap

Language：Japanese   Publisher：(公社)日本生化学会  

researchmap

Language：Japanese   Publisher：(一社)日本クリニカルパス学会  

researchmap

Language：Japanese  

CiNii Article

CiNii Books

J-GLOBAL

researchmap

Language：Japanese   Publisher：日本医療薬学会  

CiNii Article

CiNii Books

researchmap

Language：Japanese   Publisher：日本医療薬学会  

CiNii Article

CiNii Books

researchmap

Language：Japanese   Publisher：日本医療薬学会  

CiNii Article

CiNii Books

researchmap

Language：Japanese   Publisher：日本医療薬学会  

CiNii Article

CiNii Books

researchmap

Language：Japanese   Publisher：日本医療薬学会  

CiNii Article

CiNii Books

researchmap

Language：Japanese   Publisher：日本医療薬学会  

CiNii Article

CiNii Books

researchmap

Language：Japanese   Publisher：(株)南山堂  

researchmap

Language：Japanese   Publisher：(一社)日本TDM学会  

researchmap

Language：Japanese   Publisher：(公社)日本薬学会  

researchmap

Language：English   Publisher：(公社)日本薬学会  

researchmap

Language：Japanese   Publisher：(公社)日本薬学会  

researchmap

Language：Japanese   Publisher：(公社)日本薬学会  

researchmap

Language：Japanese   Publisher：(公社)日本薬学会  

researchmap

Language：Japanese   Publisher：(公社)日本薬学会  

researchmap

Language：Japanese   Publisher：(株)ジェフコーポレーション  

researchmap

Language：Japanese   Publisher：(一社)日本臨床薬理学会  

researchmap

Language：Japanese   Publisher：(一社)日本臨床薬理学会  

researchmap

Language：Japanese   Publisher：(一社)千葉県薬剤師会  

researchmap

Language：Japanese   Publisher：日本医療薬学会  

CiNii Article

CiNii Books

researchmap

Language：Japanese   Publisher：日本医療薬学会  

CiNii Article

CiNii Books

researchmap

Language：Japanese   Publisher：日本医療薬学会  

CiNii Article

CiNii Books

researchmap

Language：Japanese   Publisher：日本医療薬学会  

CiNii Article

CiNii Books

researchmap

Language：Japanese   Publisher：日本医療薬学会  

CiNii Article

CiNii Books

researchmap

Language：Japanese   Publisher：(一社)日本癌治療学会  

researchmap

Language：Japanese   Publisher：(公社)日本生化学会  

researchmap

Language：Japanese   Publisher：(公財)臨床薬理研究振興財団  

researchmap

Language：Japanese   Publisher：(一社)日本TDM学会  

researchmap

Language：Japanese   Publisher：(一社)日本遺伝カウンセリング学会  

researchmap

Language：Japanese   Publisher：(公社)日本薬学会  

researchmap

Language：Japanese   Publisher：(公社)日本薬学会  

researchmap

Language：Japanese   Publisher：(公社)日本薬学会  

researchmap

Language：Japanese   Publisher：(公社)日本薬学会  

researchmap

Language：Japanese   Publisher：(公社)日本薬学会  

researchmap

Language：Japanese   Publisher：(株)ジェフコーポレーション  

researchmap

Language：Japanese   Publisher：(株)ジェフコーポレーション  

researchmap

Language：Japanese   Publisher：(一社)日本臨床薬理学会  

researchmap

Language：Japanese   Publisher：(一社)千葉県薬剤師会  

researchmap

Language：Japanese   Publisher：(一社)日本臨床薬理学会  

researchmap

Language：Japanese   Publisher：日本医療薬学会  

CiNii Article

CiNii Books

researchmap

Language：Japanese   Publisher：日本医療薬学会  

CiNii Article

CiNii Books

researchmap